Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio

被引：26

作者：

Glueck, CJ ^{[1
]}

Khalil, Q ^{[1
]}

Winiarska, M ^{[1
]}

Wang, P ^{[1
]}

机构：

[1] Jewish Hosp Cincinnati, Ctr Cholesterol, Cincinnati, OH 45229 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 295卷 / 13期

关键词：

D O I：

10.1001/jama.295.13.1517

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1517 / 1518

页数：2

共 6 条

[1]

Caccia S, 2004, IDRUGS, V7, P143

[2]

DIVIRGILIO SN, 2002, AM SOC CLIN PHARM TH, V71, P63

[3]

Limke KK, 2002, ANN PHARMACOTHER, V36, P1890

[4] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].

NARANJO, CA ;

BUSTO, U ;

SELLERS, EM ;

SANDOR, P ;

RUIZ, I ;

ROBERTS, EA ;

JANECEK, E ;

DOMECQ, C ;

GREENBLATT, DJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245

[5] Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors [J].

Wadelius, M ;

Sörlin, K ;

Wallerman, O ;

Karlsson, J ;

Yue, QY ;

Magnusson, PKE ;

Wadelius, C ;

Melhus, H .

PHARMACOGENOMICS JOURNAL, 2004, 4 (01) :40-48

[6]

Yap K. B., 1999, SMJ, V40, P480

← 1 →